

Remarks

Please cancel claims 1-59. Please add claims 60-74. Support for the added claims can be found, *inter alia*, at pp. 14-19 of the specification.

Claims 1-59 were rejected under 35 U.S.C. 112, first paragraph as allegedly failing to comply with the written description requirement.

Claims 1-2, 5-6, 11-14, 20-22, 26-31, 34, 36-39, 41-44, and 58 were rejected under 35 U.S.C. 102(b) as allegedly being anticipated by Sasaki & Koga (*J. Inclus. Pehn. Mol. Recog. Chem.*, 1989, 7, 267-76).

Claims 1-3, 5-8, 11-13, 20, 26-29, 32, 36-37, 41-44, and 58 were rejected under 35 U.S.C. 102(b) as allegedly being anticipated by Baca et al., (*J. Am. Chem. Soc.*, 1995, 117, 1881-7).

Claims 1-59 have been canceled. It is believed that all the above rejections are mooted by new claims 60-74 and that the present claims are in condition for allowance.


Closing

Applicants submit that the present response is complete and complies with the requirements of 35 U.S.C. §121, and that all claims are now in condition for allowance. Should the Examiner have any remaining questions regarding the subject invention or its patentability, Applicant encourages the Examiner to contact the undersigned to answer such questions or provide additional information.

Applicants believe that no fee is due in association with this response. If the Applicants are in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment that may occur during the pendency of this application to Deposit Account No. 01-0535.

Dated: June 19, 2007

Respectfully submitted,



Richard San Pietro
Senior Patent Counsel

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 754-4981
Facsimile: (858) 552-1936